259 related articles for article (PubMed ID: 19211723)
1. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Migrenne S; Lacombe A; Lefèvre AL; Pruniaux MP; Guillot E; Galzin AM; Magnan C
Am J Physiol Regul Integr Comp Physiol; 2009 Apr; 296(4):R929-35. PubMed ID: 19211723
[TBL] [Abstract][Full Text] [Related]
2. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
3. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
4. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
5. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
6. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Mohapatra J; Sharma M; Singh S; Pandya G; Chatterjee A; Balaraman R; Patel PR; Jain MR
J Pharm Pharmacol; 2009 Nov; 61(11):1493-8. PubMed ID: 19903374
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways.
Watanabe T; Kubota N; Ohsugi M; Kubota T; Takamoto I; Iwabu M; Awazawa M; Katsuyama H; Hasegawa C; Tokuyama K; Moroi M; Sugi K; Yamauchi T; Noda T; Nagai R; Terauchi Y; Tobe K; Ueki K; Kadowaki T
J Biol Chem; 2009 Jan; 284(3):1803-12. PubMed ID: 19008231
[TBL] [Abstract][Full Text] [Related]
8. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Thornton-Jones ZD; Kennett GA; Benwell KR; Revell DF; Misra A; Sellwood DM; Vickers SP; Clifton PG
Pharmacol Biochem Behav; 2006 Jun; 84(2):353-9. PubMed ID: 16814374
[TBL] [Abstract][Full Text] [Related]
9. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
Poirier B; Bidouard JP; Cadrouvele C; Marniquet X; Staels B; O'Connor SE; Janiak P; Herbert JM
Diabetes Obes Metab; 2005 Jan; 7(1):65-72. PubMed ID: 15642077
[TBL] [Abstract][Full Text] [Related]
10. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
12. Does rimonabant independently affect free fatty acid and glucose metabolism?
Triay J; Mundi M; Klein S; Toledo FG; Smith SR; Abu-Lebdeh H; Jensen M
J Clin Endocrinol Metab; 2012 Mar; 97(3):819-27. PubMed ID: 22170727
[TBL] [Abstract][Full Text] [Related]
13. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
Verty AN; Lockie SH; Stefanidis A; Oldfield BJ
Int J Obes (Lond); 2013 Feb; 37(2):279-87. PubMed ID: 22473329
[TBL] [Abstract][Full Text] [Related]
14. Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
Poussin C; Hall D; Minehira K; Galzin AM; Tarussio D; Thorens B
PLoS One; 2008; 3(10):e3385. PubMed ID: 19030233
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
16. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.
Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020
[TBL] [Abstract][Full Text] [Related]
17. Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective visceral adiposity by high-fat diet: implications for insulin resistance.
Zhang H; Chen X; Aravindakshan J; Sairam MR
Endocrinology; 2007 Dec; 148(12):5667-79. PubMed ID: 17717050
[TBL] [Abstract][Full Text] [Related]
18. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Hansen HH; Hansen G; Tang-Christensen M; Larsen PJ; Axel AM; Raben A; Mikkelsen JD
Eur J Pharmacol; 2010 Jun; 636(1-3):88-95. PubMed ID: 20385125
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.
Zhang LN; Gamo Y; Sinclair R; Mitchell SE; Morgan DG; Clapham JC; Speakman JR
Obesity (Silver Spring); 2012 May; 20(5):954-62. PubMed ID: 22173576
[TBL] [Abstract][Full Text] [Related]
20. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
